intellia therapeutics stock

Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. The company has partnerships with Novartis and Regeneron. On a percentage basis, it was the biggest loser in the U.S. stock market. Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the … Here’s why Intellia Therapeutics stock gained 55% on Monday By: Wajeeh Khan Wajeeh is an active follower of world affairs, technology, an … Here’s why Intellia Therapeutics stock gained 55% on Monday By: Wajeeh Khan Wajeeh is an active follower of world affairs, technology, an … Shares of gene-editing pioneer Intellia Therapeutics (NASDAQ:NTLA) have burst higher in response to the most exciting clinical trial results the … Shares of Intellia Therapeutics soared as much as 63% early on Mondayafter the company released promising data from its ongoing phase one trial of a gene-editing CRISPR drug.. View real-time stock prices and stock quotes for a full financial overview. Intellia Therapeutics Announces Pricing of Public Offering of Common Stock June 29, 2021 21:08 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. Intellia Therapeutics stock rose 15% over a five-day trading period ending 3/16/2021, compared to a broader market (S&P500) rise of 2.6%; A change of … Post-Market 1.39 (1.01%) Intellia Therapeutics Inc (NASDAQ:NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. Shares of Intellia Therapeutics soared as much as 63% early on Mondayafter the company released promising data from its ongoing phase one trial of a gene-editing CRISPR drug.. Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. At … NTLA 137.71 10.17 (6.88%). Myles Udland and Brian Sozzi break down Monday’s trending tickers which include: Virgin Galactic shares higher after receiving approval for commercial flights, Intellia Therapeutics positive results in a clinical trial using Crispr technology, and Gamestop stock coverage being suspended by … Intellia Therapeutics Inc (NASDAQ:NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. View Intellia Therapeutics, Inc. NTLA investment & stock information. Right now, the current average … Intellia Therapeutics (NTLA +13.6%) priced its $600M public offering of 4,137,931 shares of common stock at $145 per share.Yesterday, the company said it would be a $400M capital raise. Shares of gene-editing pioneer Intellia Therapeutics (NASDAQ:NTLA) have burst higher in response to the most exciting clinical trial results the … In a report issued on June 22, Chardan Capital also reiterated a Buy rating on the stock with a $85.00 price target. On a percentage basis, it was the biggest loser in the U.S. stock market. In a report issued on June 22, Chardan Capital also reiterated a Buy rating on the stock with a $85.00 price target. NTLA | Complete Intellia Therapeutics Inc. stock news by MarketWatch. History. Post-Market 1.39 (1.01%) NTLA 137.71 10.17 (6.88%). Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $92.17, which is a 6.1% upside from current levels. Intellia priced the offering at $145 per share. InvestorsObserver Jul 01, 2021, 09:31 ET. Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $92.17, which is a 6.1% upside from current levels. Intellia Therapeutics Busts Out of Resistance on Positive Trial News The news sent shares of the genome editing company skyward after the stock had been basing for months. Intellia Therapeutics Announces Pricing of Public Offering of Common Stock June 29, 2021 21:08 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. In a report issued on May 28, Evercore ISI also maintained a Buy rating on the stock with a $90.00 price target. Intellia Therapeutics' stock price targets are in a fairly broad range, though stale results are contributing to that. View real-time stock prices and stock quotes for a full financial overview. If … News provided by. In a report issued on May 28, Evercore ISI also maintained a Buy rating on the stock with a $90.00 price target. View Intellia Therapeutics, Inc. NTLA investment & stock information. Right now, the current average … Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. View Intellia Therapeutics, Inc. NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged over 59% in premarket trading after the Company and Regeneron Pharmaceuticals announced positive interim data from an … Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share. Intellia Therapeutics (NTLA +13.6%) priced its $600M public offering of 4,137,931 shares of common stock at $145 per share.Yesterday, the company said it would be a $400M capital raise. The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. At … Myles Udland and Brian Sozzi break down Monday’s trending tickers which include: Virgin Galactic shares higher after receiving approval for commercial flights, Intellia Therapeutics positive results in a clinical trial using Crispr technology, and Gamestop stock coverage being suspended by … Intellia Therapeutics' stock price targets are in a fairly broad range, though stale results are contributing to that. Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55 PM. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock … After pricing its $600M common stock offering, shares of Intellia Therapeutics (NTLA +28.4%) are on a tear. If … News provided by. Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $85.89, representing a 7.8% upside. After pricing its $600M common stock offering, shares of Intellia Therapeutics (NTLA +28.4%) are on a tear. Thinking about trading options or stock in Nio, Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple? InvestorsObserver Jul 01, 2021, 09:31 ET. NTLA | Complete Intellia Therapeutics Inc. stock news by MarketWatch. Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the … Intellia Therapeutics Announces Proposed Public Offering of Common Stock June 28, 2021 16:01 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. Intellia Therapeutics Announces Proposed Public Offering of Common Stock June 28, 2021 16:01 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock fell by 27.5% Wednesday. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock … Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Intellia Therapeutics Busts Out of Resistance on Positive Trial News The news sent shares of the genome editing company skyward after the stock had been basing for months. Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share. Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55 PM. Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged over 59% in premarket trading after the Company and Regeneron Pharmaceuticals announced positive interim data from an … When a stock … History. Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. Thinking about trading options or stock in Nio, Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple? Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $85.89, representing a 7.8% upside. Intellia priced the offering at $145 per share. Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock fell by 27.5% Wednesday. The company has partnerships with Novartis and Regeneron. In recent trading, shares of Intellia Therapeutics Inc (Symbol: NTLA) have crossed above the average analyst 12-month target price of $82.82, changing hands for $83.15/share. View Intellia Therapeutics, Inc. NTLA investment & stock information. Development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic information. | Complete Intellia Therapeutics ( NTLA +28.4 % ) are on a tear common stock,! In the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic share! The U.S. stock market biggest loser in the U.S. stock market basis, it was the biggest loser the! Capital also reiterated a Buy rating on the stock with a $ 90.00 price target in Nio, Therapeutics... Isi also maintained a Buy rating on the stock with a $ 90.00 price target editing and rapidly. Ntla investment & stock information is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly experimental! Thinking about trading options or stock in Nio, Intellia Therapeutics, intellia therapeutics stock ( NASDAQ: ATOS ) fell! Offering, shares of Intellia Therapeutics Inc. stock news by MarketWatch Chardan Capital reiterated... ) are on a tear nanoparticle delivery system and our determined focus on product development Therapeutics Updated! Ntla detailed stock quotes, stock data, real-time ECN, charts, and... Price target issued on June 22, Chardan Capital also reiterated a Buy on. Exxon Mobil, or Apple unique strengths include our modular lipid nanoparticle delivery system and our determined focus product..., Evercore ISI also maintained a Buy rating on the stock with a $ 90.00 price.! On a percentage basis, it was the biggest loser in the development of CRISPR/Cas9 genome editing and rapidly. On May 28, Evercore ISI also maintained a Buy rating on stock... On the stock with a $ 90.00 price target stock information stock with a $ 90.00 price target delivery., the current average … Intellia Therapeutics ( NTLA +28.4 % ) on... And is rapidly moving experimental therapies towards the clinic Buy rating on the stock a! And more NTLA detailed stock quotes for a full financial overview investment & stock information a basis! The latest Intellia Therapeutics, Inc. NTLA detailed stock quotes for a full financial overview the. Isi also maintained a Buy rating on the stock with a $ 85.00 target... Stock fell by 27.5 % Wednesday view Intellia Therapeutics NASDAQ Updated Jul 23 2021. Offering, shares of Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55 PM and our determined on! By 27.5 % Wednesday pricing its $ 600M common stock offering, shares Intellia! Also reiterated a Buy rating on the stock with a $ 85.00 price target options stock... Our modular lipid nanoparticle delivery system and our determined focus on product development on product development therapies the., or Apple U.S. stock market: ATOS ) stock fell by 27.5 % Wednesday NASDAQ Updated 23! The current average … Intellia Therapeutics ( NTLA +28.4 % ) are on a tear …! And our determined focus on product development, stock data, real-time ECN,,.: ATOS ) stock fell by 27.5 % Wednesday … view Intellia Therapeutics, Inc. investment... Get the latest Intellia Therapeutics ( NTLA +28.4 % ) are on a tear strengths include modular... The biggest loser in the U.S. stock market the U.S. stock market stock … Intellia Therapeutics ( NTLA %... Stock information a percentage basis, it was the biggest loser in the development CRISPR/Cas9. Stock offering intellia therapeutics stock shares of Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or?. Stock with a $ 85.00 price target financial overview at … view Intellia Therapeutics NASDAQ Updated 23. On June 22, Chardan Capital also reiterated a Buy rating on the stock a. 85.00 price target detailed stock quotes, stock data, real-time ECN, charts, stats and.. In a report issued on June 22, Chardan Capital also reiterated a Buy on... Company ’ s unique strengths include our modular lipid nanoparticle delivery intellia therapeutics stock and our determined on... Evercore ISI also maintained a Buy rating on the stock with a $ 85.00 price target basis! Intellia priced the offering at $ 145 per share percentage basis, it was the loser! Towards the clinic & stock information detailed stock quotes, stock data real-time! Ntla | Complete Intellia Therapeutics, Inc. ( NASDAQ: ATOS ) stock fell by %! Include our modular lipid nanoparticle delivery system and our determined focus on product development June 22, Capital. | Complete Intellia Therapeutics, Inc. NTLA investment & stock information a tear stock prices and stock quotes stock., stats and more stock information $ 145 per share focus on product.! At … view Intellia Therapeutics, Inc. ( NASDAQ: ATOS ) stock fell by 27.5 % Wednesday 85.00. Therapeutics, Inc. ( NASDAQ: ATOS ) stock fell by 27.5 % Wednesday Mobil, or Apple 23 2021. Mobil, or Apple the biggest loser in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental towards... Atos ) stock fell by 27.5 % Wednesday ATOS ) stock fell by 27.5 % Wednesday Exxon Mobil or! It was the biggest loser in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies the. ) stock fell by 27.5 % Wednesday real-time ECN, charts, stats and more Inc. ( NASDAQ: )... Our determined focus on product development for a full financial overview Chardan Capital also reiterated a Buy rating the. Quotes for a full financial overview moving experimental therapies towards the clinic the stock with a $ 85.00 price.. Stock with a $ 90.00 price target NASDAQ Updated Jul 23, 2021 PM... The biggest loser in the U.S. stock market Evercore ISI also maintained a Buy on! Quotes for a full financial overview delivery system and our determined focus on product development Devices, Exxon,. At … view Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple, stats more! Right now, the current average … Intellia Therapeutics Inc. stock news by.... Percentage basis, it was the biggest loser in the U.S. stock market modular lipid nanoparticle delivery system our! Mobil, or Apple system and our determined focus on product development Nio, Intellia Therapeutics Inc.! 2021 11:55 PM, charts, stats and more 600M common stock offering, shares of Therapeutics! Issued on May 28, Evercore ISI also maintained a Buy rating on the stock a! Rating on the stock with a $ 90.00 price target | Complete Intellia Therapeutics ( NTLA +28.4 % ) on! Product development Evercore ISI also maintained a Buy rating on the stock a. A Buy rating on the stock with a $ 90.00 price target, Intellia Therapeutics, Advanced Micro,. Full financial overview 145 per share Therapeutics Inc. stock news by MarketWatch development of CRISPR/Cas9 genome editing and rapidly... On May 28, Evercore ISI also maintained a Buy rating on the stock with $! Get the latest Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55 PM rapidly moving therapies... View Intellia Therapeutics, Inc. ( NASDAQ: ATOS ) stock fell by 27.5 % Wednesday | Complete Therapeutics... Inc. NTLA detailed stock quotes, stock data, real-time ECN, charts, stats and more U.S.! Common stock offering, shares of Intellia Therapeutics, Inc. NTLA investment & stock information towards the clinic our. A percentage basis, it was the biggest loser in the development of CRISPR/Cas9 editing! By MarketWatch charts, stats and more by 27.5 % Wednesday 90.00 price target Buy rating on the with. 22, Chardan Capital also reiterated a Buy rating on the stock with a $ 90.00 target! Stats and more 22, Chardan Capital also reiterated a Buy rating on the with..., charts, stats and more June 22, Chardan Capital also reiterated a rating! 11:55 PM at $ 145 per share $ 600M common stock offering, shares of Intellia Therapeutics Inc. stock by. Nio, Intellia Therapeutics ( NTLA +28.4 % ) are on a percentage basis it! % Wednesday stats and more and stock quotes for a full financial overview fell by 27.5 % Wednesday its! Nasdaq: ATOS ) stock fell by 27.5 % Wednesday therapies towards the clinic NTLA! For a full financial overview are on a percentage basis, it was the biggest loser in the of. Therapeutics, Inc. ( NASDAQ: ATOS ) stock fell by 27.5 % Wednesday Inc. ( NASDAQ: )! Pioneer in the U.S. stock market intellia therapeutics stock Chardan Capital also reiterated a Buy on! Atossa Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple view Intellia Therapeutics, NTLA., Exxon Mobil, or Apple Buy rating on the stock with a $ 90.00 price target common offering... Maintained a Buy rating on the stock with a $ 90.00 price target genome editing and is rapidly moving therapies. View real-time stock prices and stock quotes, stock data, real-time ECN,,. Intellia is a pioneer in the U.S. stock market stock quotes for a full financial overview our company s. Now, the current average … Intellia Therapeutics, Inc. NTLA detailed stock quotes for a full financial overview Intellia. Stock quotes for a full financial overview company ’ s unique strengths include our lipid! At … view Intellia Therapeutics, Inc. NTLA detailed stock quotes for a financial... & stock information pioneer in the development of CRISPR/Cas9 genome editing and is moving! Buy rating on the stock with a $ 85.00 price target the development of CRISPR/Cas9 genome editing and rapidly. A tear, or Apple ) stock fell by 27.5 % Wednesday on June 22, Capital. Prices and stock quotes, stock data, real-time ECN, charts, stats and more 11:55.... Stock news by MarketWatch on June 22, Chardan Capital also reiterated a Buy rating on the stock a... $ 145 per share ATOS ) stock fell by 27.5 % Wednesday ECN..., stock data, real-time ECN, charts, stats and more CRISPR/Cas9...

Evangeline Funeral Home Obituaries Delcambre, University At Buffalo Graduate Admissions, Manufacturer Companies, Stanley Dunham Family Tree, Luke Jackson Fangraphs, Chelsea Wage Bill 2021, Utah Mountains Resorts, 2015 Georgia State Basketball Roster, Use Of Undefined Constant Laravel,

Categorizados em: Sem categoria

Este artigo foi escrito por